At a time when the count of coronavirus cases in the country has exceeded one million, the Indian Medical Association (IMA) has said that community spread has started and the situation is quite bad.
While speaking to ANI, Dr V K Monga, the Chairman of IMA Hospital Board of India, said: "This is now an exponential growth. Every day the number of cases is increasing by more than around 30,000. This is really a bad situation for the country. There are so many factors connected with it but overall this is now spreading to rural areas. This is a bad sign. It now shows a community spread."
According to the latest health ministry update, the total confirmed cases in India have reached 1,038,716. Of these, 358,629 are active cases and 653,751 cured/discharged/migrated cases. A total of 26,273 deaths have been registered to date.
Dr Monga further said, "Cases are penetrating down into towns and villages where it will be very difficult to control the situation. In Delhi, we were able to contain it, but what about interior parts of the country in Maharashtra, Karnataka, Kerala, Goa, Madhya Pradesh (which may be the new hotspots)?"
"All these issues are very important and the state governments should take full care and seek help of the Central government to control the situation," Monga said.
As many as 13,433,742 samples have been tested for Covid-19 till July 17. Of these 361,024 samples were tested on Friday, Indian Council of Medical Research (ICMR) said.
ICMR is ramping up testing facilities regularly. At present, 885 government laboratories and 368 private laboratory chains are conducting COVID-19 tests across the country.
"This is a viral disease that spreads very fast. To contain the disease there are only two options. Firstly, 70 per cent population contracts the disease and gets immune, and other is getting an immunisation," stated Monga.
Vaccination, being the greatest hope to contain Covid-19, India's two indigenous vaccine makers would be starting human trials soon.
"There has to be phases of trials then human trial, then efficacy and side effects. Also, importantly it has to be seen how long this immunity will last because most of the patients are unable to go beyond three months of immunity," said Dr Monga.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)